Research Article
Safety Analysis of Apatinib Combined with Chemotherapy in the Treatment of Advanced Gastric Carcinoma: A Randomised Controlled Trial
Table 1
Comparison of clinical data.
| Items | SG (n = 37) | RG (n = 37) | χ2/t | |
| Gender | 0.492 | 0.483 | Male | 22 (59.46%) | 19 (51.35%) | Female | 15 (40.54%) | 18 (48.65%) | Average age (years old) | 53.21 ± 6.51 | 53.25 ± 6.38 | 0.027 | 0.979 | Average BMI (kg/m2) | 22.84 ± 1.73 | 22.86 ± 1.78 | 0.049 | 0.961 | Pathological staging | 0.237 | 0.626 | III | 23 (62.16%) | 25 (67.57%) | IV | 14 (37.84%) | 12 (32.43%) | Pathological types | | | Poorly differentiated adenocarcinoma | 16 (43.24%) | 14 (37.84%) | 1.458 | 0.227 | Medium differentiated adenocarcinoma | 17 (45.95%) | 18 (48.65%) | 0.046 | 0.831 | Carcinoma mucocellulare | 4 (10.81%) | 5 (13.51%) | 0.127 | 0.722 | Organ metastasis types | 0.237 | 0.626 | Single organ metastasis | 14 (37.84%) | 12 (32.43%) | Multiple organ metastasis | 23 (62.16%) | 25 (67.57%) | Residence | 0.218 | 0.641 | Urban area | 19 (51.35%) | 21 (56.76%) | Rural area | 18 (48.65%) | 16 (43.24%) |
|
|